Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
A DNA microarray or chip is a semiconductor surface on which sequences of many varied genes are bonded to probes. DNA microarrays are used to quantify expression levels of numbers of genes simultaneously or to genotype multiple regions of a genome. The approach finds application in drug R&D, clinical diagnosis, agriculture, environment control, and other sectors.
The global DNA/gene microarray market is estimated to account for US$ 3,018.3 Mn in terms of value in 2020 and is expected to reach US$ 7,693.0 Mn by the end of 2027.
Global DNA/Gene Microarray Market: Drivers
Increasing adoption of genetic testing is expected to propel growth of the global DNA/gene microarray market over the forecast period. For instance, in April 2020, Axovant Gene Therapies collaborated with Invitae Corporation, a provider of advanced medical genetics, to offer free genetic testing in the U.S. and Canada for pediatric lysosomal storage disease.
Moreover, development of novel microarray technology is also expected to fuel growth of the global DNA/gene microarray market over the forecast period. For instance, in December 2019, PathogenDx, Inc. was awarded two US Patents for Tandem PCR + Microarray Hybridisation technology.
North America held dominant position in the global DNA/gene microarray market in 2019, accounting for 34.1% share in terms of value, followed by Europe and Asia Pacific, respectively
Figure 1. Global DNA/Gene Microarray Market Share (%), by Value, by Region, 2019
Global DNA/Gene Microarray Market: Restraints
Lack of technically trained resources, especially in emerging economies, is expected to hinder growth of the global DNA/gene microarray market. Technologically versed and skilled resources are a prerequisite for using DNA/gene microarrays and sequencers. Shortage of such trained personnel is expected to limit market growth.
Moreover, chip compatibility issues are also expected to limit the market growth. A company’s microarray is compatible only with its scanner, fluidics station, autoloader, and operating software alone wherein the manufacturers strive to maintain proprietary rights by following a closed system. Such system specificity principle is believed to create entry barriers for upcoming and new players in the market.
Global DNA/Gene Microarray Market: Opportunities
R&D in cancer is expected to offer lucrative growth opportunities for players in the market. For instance, in April 2020, researchers from National Defense Medical Center, Taiwan, reported use of DNA microarray gene expression profiles in a research to assess the immunofunctionomes of ovarian clear cell carcinoma in early and advanced stages.
Moreover, increasing prevalence of cancer is also expected to aid in growth of the market. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.
The global DNA/gene microarray market was valued at US$ 2,640.7 Mn in 2019 and is forecast to reach a value of US$ 7,693.0 Mn by 2027 at a CAGR of 12.4% between 2020 and 2027.
Figure 2. Global DNA/Gene Microarray Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027
Market Trends/Key Takeaways
DNA microarray is effective and accurate in determining the presence of pathogens in cannabis. According to a November 2019 study results released by PathogenDx, Inc., end-point PCR technologies such as Sequencing and DNA microarray are more accurate in determining the presence of pathogens in cannabis.
Single Nucleotide Polymorphism (SNP) chips have found to give false positive results. According to a study published in the journal bioRxiv in June 2019, SNP chips used by direct-to-consumer genetic testing companies have a false discovery rate of over 85% when screening for very rare variants.
Global DNA/Gene Microarray Market: Competitive Landscape
Major players operating in the global DNA/gene microarray market include, Affymetrix, Inc., Illumina, Inc., Agilent Technologies Inc., Roche NimbleGen Inc., Sequenom, Inc., Biometrix Technology Inc., LC Sciences, Life Technologies Corp., Lifegen Technologies LLC, Microarrays Inc.
Global DNA/Gene Microarray Market: Key Developments
Major players in the market are focused on launching new products to expand their product portfolio. For instance, in March 2020, Agilent Technologies Inc. launched Agilent GenetiSure Cyto microarrays for prenatal and postnatal research.
Major players in the market are also focused on adopting collaboration and partnership strategies to enhance their market share. For instance, in July 2019, PathogenDx, Inc. entered into a strategic sales and service distribution partnership with Zef Scientific in Canada.